|Dr. Brian Ward||Founder, CEO, MD & Exec. Director||N/A||N/A||N/A|
|Mr. James Agnew||CFO & Company Sec.||N/A||N/A||N/A|
|Ms. Simone Von Fircks||VP of Operations||N/A||N/A||N/A|
|Dr. Barnaby C.H. May||VP of Technology||N/A||N/A||N/A|
|Ms. Tracy Weimar BA, MBA||Company Sec.||N/A||N/A||N/A|
Aroa Biosurgery Limited, a regenerative medicine company, develops and manufactures medical devices for wound and tissue repair in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobia for treating acute and chronic wounds; Myriad, an implant and dermal procedures for soft tissue repair, reinforcement, and complex wounds; and Reinforced Bioscaffolds, a biologics and synthetics product used in surgical ventral hernia repair solutions. The company was founded in 2008 and is based in Auckland, New Zealand.
Aroa Biosurgery Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.